<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sinclair, Heather Q.</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Patkar, Ashwin</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Ziprasidone Therapy in the Acute Depressive Mixed State</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">11-11</style></pages><abstract><style  face="normal" font="default" size="100%">Ziprasidone demonstrated efficacy and tolerability among patients with depressive mixed state, according to a recent study. In this double-blind, placebo-controlled, multicenter trial that included 74 patients who met DSM-IV criteria for major depressive disorder and two to three DSM-IV mania criteria, patients were randomized to receive either ziprasidone 40–160 mg/daily (n=36) or placebo (n=38) for 6 weeks in a forced titration regimen.</style></abstract><number><style face="normal" font="default" size="100%">4</style></number><volume><style face="normal" font="default" size="100%">10</style></volume></record></records></xml>